Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingnao Shuluo is a Traditional Chinese Medicine (TCM) formulation developed by Changsha Dynamic Energy Biotechnology Co., Ltd., specifically indicated for the treatment and rehabilitation of cerebral infarction and ischemic stroke. The name translates to "awakening the brain and dredging the collaterals," reflecting its therapeutic goals of restoring consciousness and improving microcirculation. The formulation typically leverages the synergistic effects of herbal extracts such as *Panax notoginseng* and *Ligusticum chuanxiong*. Its mechanism of action involves the inhibition of platelet aggregation, reduction of blood viscosity, and the promotion of cerebral blood flow. Additionally, it provides neuroprotective effects by mitigating oxidative stress and inflammatory responses in neural tissues following ischemic injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xingnao Shuluo.